Cargando…

The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin

Detalles Bibliográficos
Autores principales:	Prandoni, Paolo, Cattelan, Anna Maria, Carrozzi, Laura, Leone, Lucia, Filippi, Lucia, De Gaudenzi, Egidio, Villalta, Sabina, Pesavento, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Letter to the Editors-in-Chief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497738/ https://www.ncbi.nlm.nih.gov/pubmed/33007739 http://dx.doi.org/10.1016/j.thromres.2020.09.024

Ejemplares similares

Fondaparinux and bleeding risk in COVID-19: unsolved question
por: Russo, Vincenzo, et al.
Publicado: (2021)

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data
por: Soeiro, Alexandre de Matos, et al.
Publicado: (2016)

Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19
por: Zermatten, Maxime G., et al.
Publicado: (2020)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Thrombotic complications in critically ill patients with COVID 19
por: Rosen, Raphael J.
Publicado: (2020)

Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5)
por: Alfonso Ross Terres, Jorge, et al.
Publicado: (2015)

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
por: Cardillo, Giuseppe, et al.
Publicado: (2021)

Enoxaparin-sodium/fondaparinux-sodium: Major and clinically relevant bleeding complications: 8 case reports
Publicado: (2020)

Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
por: Siguret, Virginie, et al.
Publicado: (2020)

A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients
por: Adam, E.H., et al.
Publicado: (2020)

Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis
por: Dong, Wen-Jun, et al.
Publicado: (2016)

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux
por: Prandoni, Paolo, et al.
Publicado: (2021)

Clotting abnormalities in critically ill COVID-19 patients are inconsistent with overt disseminated intravascular coagulation
por: Paparella, Domenico, et al.
Publicado: (2020)

Bacterial surinfection and venous thromboembolism in critically ill ICU patients with COVID-19: What is the relationship?
por: Stessel, Björn, et al.
Publicado: (2021)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: A multicenter case-control study
por: Smit, Jasper M., et al.
Publicado: (2021)

Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study
por: Godon, Alexandre, et al.
Publicado: (2021)

Pharmacokinetics of enoxaparin in COVID-19 critically ill patients
por: Zufferey, Paul Jacques, et al.
Publicado: (2021)

Fondaparinux in a critically Ill patient with heparin-induced thrombocytopenia: A case report
por: He, Yumiao, et al.
Publicado: (2018)

The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018)

Serial fibrin monomer and D-dimer plasma levels measurements can capture thrombotic complications in critically ill COVID-19 patients: A prospective observational study
por: Hardy, M., et al.
Publicado: (2023)

Anti-activated factor × response to enoxaparin in critically ill patients
por: Einav, S, et al.
Publicado: (2009)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study
por: Ramakrishna, Pinjala, et al.
Publicado: (2021)

Fondaparinux-associated Thrombocytopenia
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
por: Priglinger, U, et al.
Publicado: (2002)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study
por: Guo, Yanqing, et al.
Publicado: (2023)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

When Will Fondaparinux Induce Thrombocytopenia?
por: Chen, Li-Yu, et al.
Publicado: (2022)

Design and Synthesis of Neutralizable Fondaparinux
por: Zhang, Liangwei, et al.
Publicado: (2022)

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine
por: Leone, Maria Cristina, et al.
Publicado: (2022)

Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units
por: Doyle, Andrew J., et al.
Publicado: (2020)

Management of acute coronary syndromes with fondaparinux
por: Wienbergen, Harm, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_8a5lcmee36blgd5keal18m5ttb